Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron D Goldberg

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Haematologica|May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic DiseasesTalha Badar, Ahmad Nanaa, Ehab Atallah, et al.
JCO Precision Oncology|May 13, 2020
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel TherapyUmut Aypar, Justin Taylor, Jacqueline S Garcia, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Haematologica|January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalitiesLeora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Nature|October 29, 2020
Single-cell mutation analysis of clonal evolution in myeloid malignanciesLinde A Miles, Robert L Bowman, Tiffany R Merlinsky, et al.
Blood Neoplasia|March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogeneticsLuis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Haematologica|May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic DiseasesTalha Badar, Ahmad Nanaa, Ehab Atallah, et al.
JCO Precision Oncology|May 13, 2020
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel TherapyUmut Aypar, Justin Taylor, Jacqueline S Garcia, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Haematologica|January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalitiesLeora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Nature|October 29, 2020
Single-cell mutation analysis of clonal evolution in myeloid malignanciesLinde A Miles, Robert L Bowman, Tiffany R Merlinsky, et al.
Blood Neoplasia|March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogeneticsLuis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Pageof 7